Abstract
Ischemic stroke causes cell necrosis with the exposure of extracellular ribonucleic acid (RNA) and other intracellular material. As shown recently, extracellular RNA impaired the blood-brain-barrier and contributed to vasogenic edema-formation. Application of ribonuclease 1 (RNase 1) diminished edema-formation and also reduced lesion volume in experimental stroke. Here we investigate whether reduction of lesion volume is due to the reduction of edema or of other neuroprotective means. Neuroprotective and edema protective effects of RNase 1 pretreatment were assessed using a temporary middle cerebral artery occlusion (MCAO) model in rats. Lesion volume was assessed on magnetic resonance imaging (MRI). T2- relaxation-time and midline-shift as well as brain water content (wet-dry-method) were measured to quantify edema formation. The impact of edema formation on infarct volume was evaluated in craniectomized animals. Exogenous RNase 1 was well tolerated and reduced edema-formation and infarct size (26.7% ± 10.7% vs. 41.0% ± 10.3%; p < 0.01) at an optimal dose of 42 μg/kg as compared to placebo. Craniectomized animals displayed a comparable edema reduction but no reduction in infarct size. The present study introduces a hitherto unrecognized mechanism of ischemic brain damage and a novel neuroprotective approach towards acute stroke treatment.
Keywords: Acute stroke, edema, RNase, neuroprotection, craniectomy
Current Neurovascular Research
Title: RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke
Volume: 6 Issue: 1
Author(s): Maureen Walberer, Marlene Tschernatsch, Silvia Fischer, Nouha Ritschel, Kai Volk, Carolin Friedrich, Georg Bachmann, Clemens Mueller, Manfred Kaps, Max Nedelmann, Franz Blaes, Klaus T. Preissner and Tibo Gerriets
Affiliation:
Keywords: Acute stroke, edema, RNase, neuroprotection, craniectomy
Abstract: Ischemic stroke causes cell necrosis with the exposure of extracellular ribonucleic acid (RNA) and other intracellular material. As shown recently, extracellular RNA impaired the blood-brain-barrier and contributed to vasogenic edema-formation. Application of ribonuclease 1 (RNase 1) diminished edema-formation and also reduced lesion volume in experimental stroke. Here we investigate whether reduction of lesion volume is due to the reduction of edema or of other neuroprotective means. Neuroprotective and edema protective effects of RNase 1 pretreatment were assessed using a temporary middle cerebral artery occlusion (MCAO) model in rats. Lesion volume was assessed on magnetic resonance imaging (MRI). T2- relaxation-time and midline-shift as well as brain water content (wet-dry-method) were measured to quantify edema formation. The impact of edema formation on infarct volume was evaluated in craniectomized animals. Exogenous RNase 1 was well tolerated and reduced edema-formation and infarct size (26.7% ± 10.7% vs. 41.0% ± 10.3%; p < 0.01) at an optimal dose of 42 μg/kg as compared to placebo. Craniectomized animals displayed a comparable edema reduction but no reduction in infarct size. The present study introduces a hitherto unrecognized mechanism of ischemic brain damage and a novel neuroprotective approach towards acute stroke treatment.
Export Options
About this article
Cite this article as:
Walberer Maureen, Tschernatsch Marlene, Fischer Silvia, Ritschel Nouha, Volk Kai, Friedrich Carolin, Bachmann Georg, Mueller Clemens, Kaps Manfred, Nedelmann Max, Blaes Franz, Preissner T. Klaus and Gerriets Tibo, RNase Therapy Assessed by Magnetic Resonance Imaging Reduces Cerebral Edema and Infarction Size in Acute Stroke, Current Neurovascular Research 2009; 6 (1) . https://dx.doi.org/10.2174/156720209787466037
DOI https://dx.doi.org/10.2174/156720209787466037 |
Print ISSN 1567-2026 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5739 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Anti-cancer Therapies in High Grade Gliomas
Current Proteomics Brain-Derived Neurotrophic Factor and Antidepressant Activity
Current Pharmaceutical Design Scientific Basis for the Use of Indian Ayurvedic Medicinal Plants in the Treatment of Neurodegenerative Disorders: 1. Ashwagandha
Central Nervous System Agents in Medicinal Chemistry Basis for the Application of Analytical Models of the Bloch NMR Flow Equations for Functional Magnetic Resonance Imaging (fMRI): A Review
Recent Patents on Medical Imaging Immunomodulatory Properties of Antibiotics
Current Molecular Pharmacology Surgical Ventricular Restoration to Reverse Left Ventricular Remodeling
Current Cardiology Reviews Advent and Maturation of Regenerative Medicine
Current Stem Cell Research & Therapy Recent Evidence of the Regulatory Role of PPARs in Neural Stem Cells and Their Underlying Mechanisms for Neuroprotective Effects
Current Stem Cell Research & Therapy Management of Hypertension in the Acute Phase of Stroke
Current Hypertension Reviews Growth Restriction: Etiology, Maternal and Neonatal Outcome. A Review
Current Women`s Health Reviews Aggressive Antioxidant Reductive Stress Impairs Brain Endothelial Cell Angiogenesis and Blood Brain Barrier Function
Current Neurovascular Research Brain Drug Delivery System: An Overview
Current Drug Therapy Recent Advances in Neuroinflammation Therapeutics: PPARs/LXR as Neuroinflammatory Modulators
Current Pharmaceutical Design Myalgic Encephalomyelitis: Symptoms and Biomarkers
Current Neuropharmacology Metalloproteinases and Metalloproteinase Inhibitors in Age-Related Diseases
Current Pharmaceutical Design Erythropoietin Signaling and Neuroprotection
Current Signal Transduction Therapy Clinical Uses of Melatonin in Neurological Diseases and Mental and Behavioural Disorders
Current Medicinal Chemistry Editorial (Thematic Issue: Targeting Phosphodiesterases (PDEs) for Treatment of CNS Diseases)
Current Pharmaceutical Design Host-Pathogen Interactions and the Pathological Consequences of Acute Systemic Candida albicans Infections in Mice
Current Drug Targets Inflammatory Process in Alzheimer’s and Parkinson's Diseases: Central Role of Cytokines
Current Pharmaceutical Design